Renaissance Capital logo

ACRS News

Dermatology biotech Sienna Biopharmaceuticals sets terms for $65 million IPO

SNNA

Sienna Biopharmaceuticals, a clinical-stage biotech developing topical therapies for dermatological conditions, announced terms for its IPO on Monday. The Westlake Village, CA-based company plans to raise $65 million by offering 4.3 million shares at a price range of $14 to $16. Insiders intend to purchase $25 million worth of shares in the offering. At the midpoint of the...read more

US IPO Weekly Recap: Cut the offer price for positive returns

PSTG

Continuing the recent trend, four out of five deals priced below the range. This week, five companies raised $765 million, pricing an average of 19% below their proposed midpoints. All four deals that priced below traded up, popping 10% on average and ending the week up 12%; the one that priced in its range dropped 6% in its first day and ended the week down...read more

Aclaris Therapeutics prices IPO at $11, below the range

Aclaris Therapeutics, which is developing a proprietary hydrogen peroxide treatment for common skin lesions, raised $55 million by offering 5 million shares at $11, below the range of $14 to $16. Aclaris Therapeutics plans to list on the Nasdaq under the symbol ACRS. Jefferies and Citi acted as lead managers on the deal....read more

Week ahead: Fourth quarter kicks off with 11 IPOs set for the week of October 5

PSTG

As many as 11 companies could go public this week, including the year's largest IPO (Digicel) and the fastest-growing company (Pure Storage). Both have proposed market caps of more than $3.5 billion, while six others target valuations of $300 million or less. Last week, there were also 11 IPOs set to price, but ...read more